title: Weekly chemotherapy with cisplatin and paclitaxel and concurrent radiation therapy as preoperative treatment in locally advanced esophageal cancer: a phase II study.
abstract: We evaluated the association of a weekly cisplatin (35 mg/mq) and paclitaxel (45 mg/mq) regimen with radiotherapy (46 Gy) as primary treatment in locally advanced esophageal cancer (LAEC). The main end point was the activity in terms of pathologic complete response (pathCR) rate. Thirty-three LAEC patients received chemoradiation therapy during weeks 1-6 followed by esophagectomy. A pathCR was observed in 10/33 patients; 20/33 and 3/33 patients showed PR and SD, respectively. The EUS maximal transverse cross sectional area reduction >50% significantly correlated with pathCR. Three-year survival rate was 35%. These results support the activity and mild toxicity of this regimen.
authors.affiliation: Division of Medical Oncology, Department of Clinical and Experimental Medicine and Surgery F. Magrassi e A. Lanzara, Second University of Naples, School of Medicine, Naples, Italy.
authors.forename: Michele
authors.initials: M
authors.lastname: Orditura
authors.forename: Gennaro
authors.initials: G
authors.lastname: Galizia
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Napolitano
authors.forename: Erika
authors.initials: E
authors.lastname: Martinelli
authors.forename: Roberto
authors.initials: R
authors.lastname: Pacelli
authors.forename: Eva
authors.initials: E
authors.lastname: Lieto
authors.forename: Gaetano
authors.initials: G
authors.lastname: Aurilio
authors.forename: Loredana
authors.initials: L
authors.lastname: Vecchione
authors.forename: Floriana
authors.initials: F
authors.lastname: Morgillo
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Catalano
authors.forename: Fortunato
authors.initials: F
authors.lastname: Ciardiello
authors.forename: Alberto
authors.initials: A
authors.lastname: Del Genio
authors.forename: Natale
authors.initials: N
authors.lastname: Di Martino
authors.forename: Ferdinando
authors.initials: F
authors.lastname: De Vita
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001706:Biopsy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003131:Combined Modality Therapy / Q000379:methods*; D004334:Drug Administration Schedule; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D016629:Esophagectomy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D018579:Patient Selection; D010976:Platelet Count; D011379:Prognosis; D011878:Radiotherapy / Q000379:methods; D015996:Survival Rate; D013997:Time Factors
chemical_list: D017239:Paclitaxel; D002945:Cisplatin